C5AR1
C5a anaphylatoxin chemotactic receptor 1
As of the edition of 20 October 2026, C5AR1 (C5a anaphylatoxin chemotactic receptor 1, UniProt P21730) has 2 drugs tested at it and 4 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P21730
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 21
- Disease areas
- Immune system; Skin and connective tissue; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Blood and lymph; Bones, joints and muscles
- Registered trials of its drugs
- 27
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Avacopan | Marketed | Phase 4 | Ends 2039 |
| Avdoralimab | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Amgen | Route B |
| Innate Pharma | Route A |
The other 2 companies at C5AR1
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at C5AR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.